Advisors



Simon Douglas Ph.D. - Commercial advisor

Simon has over 25 years’ experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was sold to Agilent Technologies Inc and is currently a director of the antibody-based therapeutics Company Fusion Antibodies.


Laurence Lovat - Prof., Ph.D., M.B.B.S., B.Sc. - Clinical advisor

Laurence is a professor of gastroenterology and biophotonics at UCL. He is chief investigator for a large multi-centre project to investigate he detection and treatment of oesophageal cancer, with key connections in the main specialist centres for oesophageal cancer in the UK. He is also special advisor to NICE (National Institute for Health and Care Excellence) who produce evidence based guidance and advice for the NHS and public health and social care services.


Marco Novelli - Prof. Ph.D. - Hisopathologial advisor

Professor Marco Novelli is a consultant histopathologist at UCLH specialising in colorectal tumorigenesis, Barrett's oesophagus, inflammatory bowel disease and gastrointestinal stromal tumours.



Caroline Potts - Clinical trials co-ordinator

Caroline has over 12 years of NHS R&D experience and oversees the running and management of a number of NIHR funded studies. More recently, Caroline has worked on developing a unique partnership between the Trust and Synexus Ltd to offer a wider portfolio of clinical trials, previously unavailable to the NHS, to the population of Northumberland and North Tyneside. The partnership is the first of its kind and has attracted international interest from both the pharmaceutical industry and the wider public sector. Caroline has also developed a dedicated software solution, IMPaCT, designed specifically to support the running of clinical trials in the NHS R&D environment. The focus of the software enables R&D departments and trial support departments, such as Pharmacy and Radiology, to track patient progress through patient progression through studies.



Tom Fearn - Prof., Ph.D. - Statistical advisor

Tom is Head of Statistics at UCL and has over 30 years experience working with clinical research groups producing statistically robust data.